Effect of eicosapentaenoic acid in patients with refractory myelodysplastic syndrome.
Okamoto
Takahiro
T
Okada
Masaya
M
Wakae
Takeshi
T
Takatsuka
Hiroyuki
H
Kakishita
Eizo
E
D000368:Aged; D001095:Arachidonic Acids / Q000627:therapeutic use*; D001803:Blood Transfusion; D001853:Bone Marrow / Q000473:pathology; D016572:Cyclosporine / Q000627:therapeutic use; D006490:Hemostatics / Q000627:therapeutic use; D006801:Humans; D008297:Male; D009190:Myelodysplastic Syndromes / Q000097:blood / Q000175:diagnosis / Q000628:therapy*; D010976:Platelet Count; D016896:Treatment Outcome; D024482:Vitamin K 2 / Q000031:analogs & derivatives* / Q000627:therapeutic use
D001095:Arachidonic Acids; D006490:Hemostatics; D024482:Vitamin K 2; C030814:menatetrenone; D016572:Cyclosporine